Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.

Alvarez-Larrán A, Pereira A, Magaz M, Hernández-Boluda JC, Garrote M, Cuevas B, Ferrer-Marín F, Gómez-Casares MT, García-Gutiérrez V, Mata-Vázquez MI, Turon F, Hernandez-Gea V, Arellano-Rodrigo E, Cervantes F, García-Pagán JC; GEMFIN and REHEVASC groups.

Ann Hematol. 2020 Feb 22. doi: 10.1007/s00277-020-03965-z. [Epub ahead of print]

PMID:
32086587
2.

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.

Pastor-Galán I, Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Ayala R, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Arbelo E, Angona A, Magro E, Antelo ML, Somolinos N, Cervantes F; en representación del Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN).

Med Clin (Barc). 2020 Jan 21. pii: S0025-7753(19)30716-X. doi: 10.1016/j.medcli.2019.11.007. [Epub ahead of print] English, Spanish.

PMID:
31980217
3.

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.

Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH.

Leuk Lymphoma. 2020 Mar;61(3):650-659. doi: 10.1080/10428194.2019.1675879. Epub 2019 Oct 24.

PMID:
31647335
4.

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Osorio S, Escudero-Vilaplana V, Gómez-Centurión I, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutierrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JÁ, Sánchez-Guijo F, Martínez-García AB, Villalón L, Conesa-García V, Rodriguez A, Casado F, Garcia-Gonzalez X, Sáez Perdomo MN, Baños Ú, Steegmann JL; CML Spanish Group (GELMC).

Ann Hematol. 2018 Nov;97(11):2089-2098. doi: 10.1007/s00277-018-3413-7. Epub 2018 Jun 28.

PMID:
29955943
5.

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, Garcia-Gutierrez V, Gattermann N, le Coutre PD, Martino B, Saussele S, Giles FJ, Radich JP, Saglio G, Deng W, Krunic N, Bédoucha V, Gopalakrishna P, Hochhaus A.

J Cancer Res Clin Oncol. 2018 May;144(5):945-954. doi: 10.1007/s00432-018-2604-x. Epub 2018 Feb 22.

6.

Prognostic risk models for transplant decision-making in myelofibrosis.

Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Gómez M, Cervantes F.

Ann Hematol. 2018 May;97(5):813-820. doi: 10.1007/s00277-018-3240-x. Epub 2018 Jan 25.

PMID:
29396714
7.

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188. doi: 10.1007/s00432-017-2532-1.

8.

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.

Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez-Encinas M, Estrada N, Velez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F.

Leukemia. 2018 Feb;32(2):553-555. doi: 10.1038/leu.2017.297. Epub 2017 Sep 22. No abstract available.

PMID:
28935991
9.

PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase.

Alonso-Dominguez JM, Casado LF, Anguita E, Gomez-Casares MT, Buño I, Ferrer-Marín F, Arenas A, Del Orbe R, Ayala R, Llamas P, Salgado RN, Osorio S, Sanchez-Godoy P, Burgaleta C, Mahíllo-Fernández I, Garcia-Gutierrez V, Steegmann JL, Martinez-Lopez J.

PLoS One. 2017 Jul 13;12(7):e0181366. doi: 10.1371/journal.pone.0181366. eCollection 2017.

10.

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. doi: 10.1007/s00432-017-2445-z. Epub 2017 May 27. Erratum in: J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188.

11.

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redondo S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC).

PLoS One. 2017 Mar 9;12(3):e0173532. doi: 10.1371/journal.pone.0173532. eCollection 2017.

12.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G.

Leukemia. 2017 Jul;31(7):1525-1531. doi: 10.1038/leu.2017.63. Epub 2017 Feb 20.

13.

Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis.

De-la-Iglesia S, Luzardo H, Lemes A, Torres M, Gómez-Casares MT, Cruz N, Molero T.

Hematol Rep. 2016 Sep 30;8(3):6562. eCollection 2016 Sep 28.

14.

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, García F, Burgaleta C, Besses C; Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas.

Haematologica. 2017 Jan;102(1):103-109. doi: 10.3324/haematol.2016.152769. Epub 2016 Sep 29.

15.

CALR mutation characterization in myeloproliferative neoplasms.

Bilbao-Sieyro C, Florido Y, Gómez-Casares MT.

Oncotarget. 2016 Aug 16;7(33):52614-52617. doi: 10.18632/oncotarget.10376.

16.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C.

Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12.

17.

[Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].

García-Gutiérrez V, Jiménez-Velasco A, Gómez-Casares MT, Sánchez-Guijo F, López-Sendón JL, Steegmann Olmedillas JL.

Med Clin (Barc). 2016 Jun 17;146(12):561.e1-8. doi: 10.1016/j.medcli.2016.02.022. Epub 2016 Apr 20. Spanish.

PMID:
27107729
18.

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.

Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Bárez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez-Casares MT, Besses C; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN).

Br J Haematol. 2016 Mar;172(5):786-93. doi: 10.1111/bjh.13886. Epub 2015 Dec 21.

PMID:
26898196
19.

Colony-stimulating factor-3 receptor, watch out for polymorphisms.

Bilbao-Sieyro C, Santana G, Torres-Miñana L, Rodriguez-Medina C, Saez MN, Perera M, Lemes A, de la Iglesia S, Molero T, Gomez-Casares MT.

Leukemia. 2015 Jun;29(6):1445-6. doi: 10.1038/leu.2015.25. Epub 2015 Feb 24. No abstract available.

PMID:
25708716
20.

High resolution melting analysis: a rapid and accurate method to detect CALR mutations.

Bilbao-Sieyro C, Santana G, Moreno M, Torres L, Santana-Lopez G, Rodriguez-Medina C, Perera M, Bellosillo B, de la Iglesia S, Molero T, Gomez-Casares MT.

PLoS One. 2014 Jul 28;9(7):e103511. doi: 10.1371/journal.pone.0103511. eCollection 2014.

21.

High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle.

Caraballo JM, Acosta JC, Cortés MA, Albajar M, Gómez-Casares MT, Batlle-López A, Cuadrado MA, Onaindia A, Bretones G, Llorca J, Piris MA, Colomer D, León J.

Oncotarget. 2014 Jul 15;5(13):4694-708.

22.

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C.

Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. Epub 2014 Jul 2.

PMID:
24981691
23.

[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].

Gómez Casares MT, León LG.

Med Clin (Barc). 2013 Aug 4;141(3):111-3. doi: 10.1016/j.medcli.2012.12.011. Epub 2013 Feb 22. Spanish. No abstract available.

PMID:
23462544
24.

Renin expression in acute leukaemia.

de la Iglesia S, Gómez Casares MT, López-Jorge CE.

J Renin Angiotensin Aldosterone Syst. 2013 Mar;14(1):91-2. doi: 10.1177/1470320312467559. No abstract available.

PMID:
23418283
25.

MYC oncogene in myeloid neoplasias.

Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, León J.

Clin Transl Oncol. 2013 Feb;15(2):87-94. doi: 10.1007/s12094-012-0926-8. Epub 2012 Aug 22. Review.

PMID:
22911553
26.

MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).

Gómez-Casares MT, García-Alegria E, López-Jorge CE, Ferrándiz N, Blanco R, Alvarez S, Vaqué JP, Bretones G, Caraballo JM, Sánchez-Bailón P, Delgado MD, Martín-Perez J, Cigudosa JC, León J.

Oncogene. 2013 Apr 25;32(17):2239-46. doi: 10.1038/onc.2012.246. Epub 2012 Jun 18.

PMID:
22710719
27.

Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.

Chillón MC, Gómez-Casares MT, López-Jorge CE, Rodriguez-Medina C, Molines A, Sarasquete ME, Alcoceba M, Miguel JD, Bueno C, Montes R, Ramos F, Rodríguez JN, Giraldo P, Ramírez M, García-Delgado R, Fuster JL, González-Díaz M, Menendez P.

Leukemia. 2012 Nov;26(11):2360-6. doi: 10.1038/leu.2012.161. Epub 2012 Jun 18.

PMID:
22705992
28.

Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns.

López-Jorge CE, Gómez-Casares MT, Jiménez-Velasco A, García-Bello MA, Barrios M, Lopez J, de la Iglesia S, Ramírez T, Sánchez G, Heiniger AI, Molero T.

Ann Hematol. 2012 Aug;91(8):1245-50. doi: 10.1007/s00277-012-1468-4. Epub 2012 Apr 25.

PMID:
22526369
29.

Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gómez-Casares MT, Hernández-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD.

Haematologica. 2011 Oct;96(10):1448-56. doi: 10.3324/haematol.2011.040535. Epub 2011 Jul 12.

30.

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Haematologica. 2011 Oct;96(10):1470-7. doi: 10.3324/haematol.2011.044933. Epub 2011 Jun 17.

31.

MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.

Albajar M, Gómez-Casares MT, Llorca J, Mauleon I, Vaqué JP, Acosta JC, Bermúdez A, Donato N, Delgado MD, León J.

Mol Cancer Res. 2011 May;9(5):564-76. doi: 10.1158/1541-7786.MCR-10-0356. Epub 2011 Apr 1.

32.

SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.

Bretones G, Acosta JC, Caraballo JM, Ferrándiz N, Gómez-Casares MT, Albajar M, Blanco R, Ruiz P, Hung WC, Albero MP, Perez-Roger I, León J.

J Biol Chem. 2011 Mar 18;286(11):9815-25. doi: 10.1074/jbc.M110.165977. Epub 2011 Jan 18.

33.

p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells.

Ferrandiz N, Caraballo JM, Albajar M, Gomez-Casares MT, Lopez-Jorge CE, Blanco R, Delgado MD, Leon J.

Cancer Lett. 2010 Jun 1;292(1):133-9. doi: 10.1016/j.canlet.2009.11.017. Epub 2009 Dec 29.

34.

Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents.

De la Iglesia Iñigo S, López-Jorge CE, Gómez-Casares MT, Lemes Castellano A, Martín Cabrera P, López Brito J, Suárez Cabrera A, Molero Labarta T.

Leuk Res. 2009 Jun;33(6):810-6. doi: 10.1016/j.leukres.2008.09.029. Epub 2008 Nov 17.

PMID:
19010543
35.

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.

Albajar M, Gutierrez P, Richard C, Rosa-Garrido M, Gómez-Casares MT, Steegmann JL, León J, Delgado MD.

Cancer Lett. 2008 Nov 8;270(2):328-36. doi: 10.1016/j.canlet.2008.05.024. Epub 2008 Jul 16.

36.

C-myc expression in cell lines derived from chronic myeloid leukemia.

Gómez-Casares MT, Vaqué JP, Lemes A, Molero T, Delgado MD, León J.

Haematologica. 2004 Feb;89(2):241-3. No abstract available.

37.

Acute promyelocytic leukemia developing after radiotherapy for prostate cancer in a patient with chronic lymphocytic leukemia.

Molero T, Lemes A, de la Iglesia S, Gómez Casares MT, del Mar Perera M, Jiménez S.

Cancer Genet Cytogenet. 2001 Dec;131(2):141-3.

PMID:
11750054
38.

Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.

González M, Barragán E, Bolufer P, Chillón C, Colomer D, Borstein R, Calasanz MJ, Gómez-Casares MT, Villegas A, Marugán I, Román J, Martín G, Rayón C, Debén G, Tormo M, Díaz-Mediavilla J, Esteve J, González-San Miguel J, Rivas C, Pérez-Equiza K, García-Sanz R, Capote FJ, Ribera JM, Arias J, León A, Sanz MA; Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group.

Br J Haematol. 2001 Jul;114(1):99-103.

PMID:
11472351
39.

p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.

Lemes A, Gómez Casares MT, de la Iglesia S, Matutes E, Molero MT.

Cancer Genet Cytogenet. 1999 Aug;113(1):100-2.

PMID:
10459357
40.

[Interferon alpha in the treatment of chronic myeloid leukemia. Promises, realities, and perspectives].

Steegmann JL, Granados E, Rodríguez-Salvanés F, Casado LF, Giraldo P, Lavilla E, Gómez-Casares MT, Fernández-Contreras E, Odriozola J.

Sangre (Barc). 1998 Apr;43(2):137-46. Spanish. No abstract available.

PMID:
9656775
41.

Detection of a t(8;21)(q22;q22) in a case of M5 acute monoblastic leukemia.

Molero MT, Gómez Casares MT, Valencia JM, Bueno JL, Suárez A, Ruano A, Molinés A, Campo C, Malcorra JJ.

Cancer Genet Cytogenet. 1998 Jan 15;100(2):176-8.

PMID:
9428365
42.

Central nervous system (CNS) infiltration in a case of promyelocytic leukemia.

Molero T, Valencia JM, Gómez-Casares MT.

Haematologica. 1997 Sep-Oct;82(5):637. No abstract available.

43.

Acute leg ischaemia as a presentation of hyperleukocytosis syndrome in acute myeloid leukaemia.

Mataix R, Gómez-Casares MT, Campo C, Jiménez S, Malcorra JJ.

Am J Hematol. 1996 Mar;51(3):250. No abstract available.

44.

Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells.

Delgado MD, Lerga A, Cañelles M, Gómez-Casares MT, León J.

Oncogene. 1995 Apr 20;10(8):1659-65.

PMID:
7731722
45.

Another case of pneumococcal arthritis after allogeneic bone marrow transplantation.

Gómez-Casares MT, Naranjo A, Campo C, Mataix R, Guerra L, Suarez A, Malcorra JJ.

Bone Marrow Transplant. 1995 Apr;15(4):650. No abstract available.

PMID:
7655398
46.

[Bone marrow aplasia and gold salts. Review of the literature apropos of 2 cases].

Pérez MC, Gómez Casares MT, Mataix R, Campo C, Jiménez S, Malcorra JJ.

Rev Clin Esp. 1994 Jul;194(7):540-2. Spanish.

PMID:
7938822
47.

[Chronic eosinophilic pneumonia in a patient treated with allogenic bone marrow transplantation].

Richard C, Calavia J, Loyola I, Baró J, Cuadrado MA, Gómez-Casares MT, Zurbano F, Ondiviela R, Zubizarreta A.

Med Clin (Barc). 1994 Apr 2;102(12):462-4. Review. Spanish.

PMID:
8207996
48.

Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.

Gómez-Casares MT, Delgado MD, Lerga A, Crespo P, Quincoces AF, Richard C, León J.

Leukemia. 1993 Nov;7(11):1824-33.

PMID:
8231250
49.

Induction of apolipoprotein E expression during erythroid differentiation of human K562 leukemia cells.

Crespo P, Delgado MD, Gómez-Casares MT, Cuadrado MA, Richard C, León J.

Leuk Res. 1993 Sep;17(9):771-6.

PMID:
8371577
50.

Differential expression of ras protooncogenes during in vitro differentiation of human erythroleukemia cells.

Delgado MD, Quincoces AF, Gómez-Casares MT, Martínez CA, Cuadrado MA, Richard C, León J.

Cancer Res. 1992 Nov 1;52(21):5979-84.

Supplemental Content

Loading ...
Support Center